Project Description

Taufon

(solution 4% (eye drop)) Taufonum (guttae ophthalmicae)

international nonproprietary name

Taurine/Tauforine solution 4%.

Ref

BP-0141

Pharmacotherapeutic group

Preparation for eye pathology treatment. Preparation regulating metabolic processes.

Composition of the preparation

1 ml of preparation contains 40 mg of taurine.

Pharmacological action

Pharmacodynamics

Taufonisasulfur-containingamineacidthatformsintheorganismduringcysteinetransformationprocess. The preparation enhances energetic processes, stimulates reparation and regeneration processes on diseases of dystrophic nature and on diseases accompanied by an acute impairment of tissue metabolism. Being a sulfur-containing amine acid, the preparation contributes to the normalization of cell membrane function, improves energetic and metabolism processes, maintains the persistence of electrolytic composition of cell cytoplasm, inhibits the synaptic transmission (performs a neurotransmitter function).

It induces the normalization of eye tissue metabolism on diseases of dystrophic nature.

Pharmacokinetics

After instillation it is absorbed in microquantities. It is practically not subject to oxidation in the organism tissues. It is found in the free form in the liver, in the muscles, in heart, nerve and brain tissues, in the blood (in blood corpuscles more than in the plasma). Itisexcretedbythekidney.

Indications 

The preparation is prescribed to adults on dystrophic retina diseases (comprising inherited retinal abiotrophy), cornea dystrophy, senile cataract, trauma cataract, irradiation cataract and other types of cataracts, as well as on  cornea trauma (as a stimulator of reparation processes).

special indication

Not established

special warning

Not established

Dosage and method of administration

For cataracts taufon is prescribed in the form of instillation 1 – 2 drops 2—4 times a day during 3 months. The course is repeated with a month interval. On traumas the preparation is used in the same dose during one month.

For treatment of dystrophic diseases of retina and cornea penetrating wound, taufon is administered under the conjunctiva in the dose of 0,3 ml of 4% solution once a day during 10 days. The course shall be repeated in 6 – 8 months.

On glaucoma (open-angle) the preparation is used as eye drops (instillation) 2 times a day 20—30 before instillation of timolol.

overdosage

Cases of over dosing on using the taufon eye drops have not been specified.

safety measures

Not established

Side effects

Allergic reactions.

Contraindications

Higher sensitivity to taurine.

Interactions with other medicinal preparations

In patients with glaucoma (open-angle) it has been demonstrated a significant increase of hypotension action in case of combination with timolol. The enhancement of effect is achieved by increasing the outflow easiness rate and reducing the aqueous hydatoid production.

The form of release

Solution 4% (eye drops) in vials 5 ml.